Jing-Yi Yan

Dr. Jing-Yi Yan

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Clinical Nutrition
Verified
Journal Article
Closed access
DHDong-Dong Huang
Dong-Dong Huang
GWGao-Feng Wu
Gao-Feng Wu
XLXin Luo
Xin Luo
HSHao-Nan Song
Hao-Nan Song
WWWen-Bin Wang
Wen-Bin Wang
JYJing-Yi Yan
Jing-Yi Yan

1 September 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
DHDong-Dong Huang
Dong-Dong Huang
DYDing-Ye Yu
Ding-Ye Yu
HSHao-Nan Song
Hao-Nan Song
WWWen-Bin Wang
Wen-Bin Wang
XLXin Luo
Xin Luo
JYJing-Yi Yan
Jing-Yi Yan

21 March 2022 in European Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
DHDong-Dong Huang
Dong-Dong Huang
DYDing-Ye Yu
Ding-Ye Yu
WWWen-Bin Wang
Wen-Bin Wang
HSHao-Nan Song
Hao-Nan Song
XLXin Luo
Xin Luo
JYJing-Yi Yan
Jing-Yi Yan

1 January 2019 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
JYJing-Yi Yan
Jing-Yi Yan
DCDidi Chen
Didi Chen
XCXiaolei Chen
Xiaolei Chen
XSXuecheng Sun
Xuecheng Sun
QDQiantong Dong
Qiantong Dong
WCWei Chen
Wei Chen
Imatinib is the first line of therapy for patients with metastatic or gastrointestinal stromal tumors (GIST). However, drug resistance limits the long-term effect of imatinib. Long non-coding RNAs (lncRNAs) are emerging as key players in regulating drug resistance in cancer. In this study, we investigated the association between lncRNA CCDC26 and IGF-1R in GIST and their involvement in drug resistance. Considering the key role of lncRNAs in drug resistance in cancer, we hypothesized that IGF-1R is regulated by lncRNAs. The expression of a series of reported drug resistance-related lncRNAs, including CCDC26, ARF, H19, NBR2, NEAT1, and HOTAIR, in GIST cells treated with imatinib H19 was examined at various time-points by qRT-PCR. Based on our results and published literature, CCDC26, a strongly down-regulated lncRNA following imatinib treatment, was chosen as our research target. GIST cells with high expression of CCDC26 were sensitive to imatinib treatment while knockdown of CCDC26 significantly increased the resistance to imatinib. Furthermore, we found that CCDC26 interacted with c-KIT by RNA pull down, and that CCDC26 knockdown up-regulated the expression of IGF-1R. Moreover, IGF-1R inhibition reversed CCDC26 knockdown-mediated imatinib resistance in GIST. These results indicated that treatments targeting CCDC26-IGF-1R axis would be useful in increasing sensitivity to imatinib in GIST.


7 September 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
SGShanshan Gao
Shanshan Gao
GYGang Yin
Gang Yin
QXQing Xia
Qing Xia
GWGuihai Wu
Guihai Wu
JZJinxiu Zhu
Jinxiu Zhu
XTXuerui Tang
Xuerui Tang
Background: The existing prediction models lack the generalized applicability for chronic heart failure (CHF) readmission. We aimed to develop and validate a widely applicable nomogram for the prediction of 180-day readmission to the patients.Methods: We prospectively enrolled 2,980 consecutive patients with CHF from two hospitals. A nomogram was created to predict 180-day readmission based on the selected variables. The patients were divided into three datasets for development, internal validation, and external validation (mean age: 74.2 ± 14.1, 73.8 ± 14.2, and 71.0 ± 11.7 years, respectively; sex: 50.2, 48.8, and 55.2% male, respectively). At baseline, 102 variables were submitted to the least absolute shrinkage and selection operator (Lasso) regression algorithm for variable selection. The selected variables were processed by the multivariable Cox proportional hazards regression modeling combined with univariate analysis and stepwise regression. The model was evaluated by the concordance index (C-index) and calibration plot. Finally, the nomogram was provided to visualize the results. The improvement in the regression model was calculated by the net reclassification index (NRI) (with tenfold cross-validation and 200 bootstraps).Results: Among the selected 2,980 patients, 1,696 (56.9%) were readmitted within 180 days, and 1,502 (50.4%) were men. A nomogram was established by the results of Lasso regression, univariate analysis, stepwise regression and multivariate Cox regression, as well as variables with clinical significance. The values of the C-index were 0.75 [95% confidence interval (CI): 0.72–0.79], 0.75 [95% CI: 0.69–0.81], and 0.73 [95% CI: 0.64–0.83] for the development, internal validation, and external validation datasets, respectively. Calibration plots were provided for both the internal and external validation sets. Five variables including history of acute heart failure, emergency department visit, age, blood urea nitrogen level, and beta blocker usage were considered in the final prediction model. When adding variables involving hospital discharge way, alcohol taken and left bundle branch block, the calculated values of NRI demonstrated no significant improvements.Conclusions: A nomogram for the prediction of 180-day readmission of patients with CHF was developed and validated based on five variables. The proposed methodology can improve the accurate prediction of patient readmission and have the wide applications for CHF.